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Since the 80´s, microcarriers have been used to provide growth support for adherent cells in vaccine 
biomanufacturing processes at scales up to 6000 L. Today, as yields are increasing, most newly developed 
vaccines are manufactured at smaller scales, making single-use technologies suitable. Since many anchorage 
dependent cell lines grown on microcarriers are sensitive to shear stress, some of the remaining challenges are 
to have homogenous well-suspended microcarriers and efficient oxygenation of the medium. These 
prerequisites can limit operating conditions and volumes of the bioreactor process. We show that by carefully 
selecting operating parameters, good cell growth and virus yields can be achieved in a single-use bioreactor 
system. Furthermore, the time consuming process of preparation and sterilization of the microcarriers prior to 
culture can be simplified significantly by using Cytodex™ Gamma.  
 
In this study we describe different approaches for the cultivation of Vero cells to high cell densities using 
Cytodex and/or Cytodex Gamma microcarriers in serum-free medium using ReadyToProcess WAVE™ 25 
and/or Xcellerex™ XDR-10 single-use bioreactor system. Vero cells were grown in the bioreactors and infected 
with influenza virus during exponential growth phase. The concentration of infectious virus was determined by 
50% tissue culture infective dose measurement (TCID50). Viral titers of 107 or higher were observed in all 
cultures. No significant differences in cell growth were observed between the different Cytodex microcarriers, 
and similar cell concentrations were reached in both bioreactor systems.  
 
Our results offer valuable information to facilitate design-in of single-use bioreactor systems and ready-to-use 
Cytodex Gamma microcarriers, enabling flexible future vaccine productions at smaller scales. 
 
